A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

Leukemia · 2020 · PMC7224085 · PMID 31925317

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

an increasing trendp=0.059so close (0.05 < p ≤ 0.1)

However, there was an increasing trend towards MMR in the IM/HCQ arm, and the number of ‘successes’ was 20.8% higher with IM/HCQ at 24 months (1-sided p=0.059 2-sided p = 0.090).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.